Vanguard Group Inc. Has $27.79 Million Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Vanguard Group Inc. cut its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,274,638 shares of the company's stock after selling 20,331 shares during the quarter. Vanguard Group Inc. owned approximately 4.31% of Dianthus Therapeutics worth $27,787,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. R Squared Ltd purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $26,000. KLP Kapitalforvaltning AS acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $33,000. KBC Group NV bought a new stake in Dianthus Therapeutics in the fourth quarter worth approximately $35,000. AlphaQuest LLC increased its stake in shares of Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after purchasing an additional 3,072 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Dianthus Therapeutics during the 4th quarter valued at $201,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded up $0.52 during mid-day trading on Friday, hitting $19.50. The company had a trading volume of 180,937 shares, compared to its average volume of 260,227. Dianthus Therapeutics, Inc. has a 12 month low of $13.37 and a 12 month high of $32.27. The firm has a market cap of $626.46 million, a P/E ratio of -7.80 and a beta of 1.62. The business's 50-day simple moving average is $20.24 and its 200-day simple moving average is $23.09.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million during the quarter, compared to analysts' expectations of $1.40 million. As a group, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Ratings Changes

DNTH has been the subject of a number of recent research reports. TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a "buy" rating for the company. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.